Integrating Genomics & Real-World Data to Predict Fam-Trastuzumab Deruxtecan Response in Metastatic Breast Cancer Across HER2 Subtypes
- Contextualizing the need for ADC biomarkers to identify optimized patient subpopulations
- Leveraging real-world data and genomics to evaluate associations between somatic mutations and clinical outcomes in metastatic breast cancer patients treated with T-DXd across HER2 subtypes
- Highlighting genomic findings to correlate T-DXd response and support further investigation of PIK3CA as a potential predictive biomarker of response in the HER2-low subgroup